Up-regulation of miR-630 in clear cell renal cell carcinoma is associated with lower overall survival

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 6, 2014, Pages 3318-3323

  Zhao, Jian Jun ^a,b   Chen, Peng Jie ^c   Duan, Rui Qin ^b   Li, Ke Ji ^b   Wang, Yu Zhong ^b   Li, Yong ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI UNIVERSITY OF ENGINEERING   (China)

^c HANDAN CENTRAL HOSPITAL   (China)

Author keywords

Clear cell renal cell carcinoma; MiR 630; Prognosis; Quantitative real time PCR

Indexed keywords

MICRORNA; MIRN630 MICRORNA, HUMAN; TUMOR MARKER;

AGED; BIOSYNTHESIS; FEMALE; GENETICS; HUMAN; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84904368529     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ and Epstein JI. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int 2010; 60: 1-8.
2. Montironi R, Santinelli A, Pomante R, Mazzucchelli R, Colanzi P, Filho AL and Scarpelli M. Morphometric index of adult renal cell carcinoma. Comparison with the Fuhrman grading system. Virchows Arch 2000; 437: 82-89.
3. Matsuura K, Nakada C, Mashio M, Narimatsu T, Yoshimoto T, Tanigawa M, Tsukamoto Y, Hijiya N, Takeuchi I, Nomura T, Sato F, Mimata H, Seto M and Moriyama M. Downregulation of SAV1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma. BMC Cancer 2011; 11: 523.
4. Cindolo L, Patard JJ, Chiodini P, Schips L, Ficarra V, Tostain J, de La Taille A, Altieri V, Lobel B, Zigeuner RE, Artibani W, Guille F, Abbou CC, Salzano L and Gallo C. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 2005; 104: 1362-1371.
5. Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, Cindolo L, De la Taille A, Tostain J, Mulders PF, Salomon L, Zigeuner R, Prayer-Galetti T, Chautard D, Valeri A, Lechevallier E, Descotes JL, Lang H, Mejean A and Patard JJ. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007; 25: 1316-1322.
6. Jiang Z, Chu PG, Woda BA, Liu Q, Balaji KC, Rock KL and Wu CL. Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin Cancer Res 2008; 14: 5579-5584.
7. Patil S, Ishill N, Deluca J and Motzer RJ. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation. Cancer 2010; 116: 347-354.
8. Farazi TA, Spitzer JI, Morozov P and Tuschl T. miRNAs in human cancer. J Pathol 2011; 223: 102-115.
9. Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM and Zhang GZ. Biological functions of microRNAs: a review. J Physiol Biochem 2011; 67: 129-139.
10. Srivastava K and Srivastava A. Comprehensive review of genetic association studies and meta-analyses on miRNA polymorphisms and cancer risk. PLoS One 2012; 7: e50966.
11. Pereira DM, Rodrigues PM, Borralho PM and Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today 2013; 18: 282-289.
12. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T and Visakorpi T. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 2011; 59: 671-681.
13. Juan D, Alexe G, Antes T, Liu H, Madabhushi A, Delisi C, Ganesan S, Bhanot G and Liou LS. Identification of a microRNA panel for clear-cell kidney cancer. Urology 2010; 75: 835-841.
14. Iorio MV and Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4: 143-159.
15. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, Servant N, Paccard C, Hupe P, Robert T, Ripoche H, Lazar V, Harel-Bellan A, Dessen P, Barillot E and Kroemer G. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010; 70: 1793-1803.
16. Chu D, Zhao Z, Li Y, Li J, Zheng J, Wang W, Zhao Q and Ji G. Increased MicroRNA-630 Expression in Gastric Cancer Is Associated with Poor Overall Survival. PLoS One 2014; 9: e90526.
17. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rüdiger T, Ströbel P, Riedmiller H and Kneitz B. Expression of microRNA221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 2010; 127: 394-403.
18. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF and Sinescu IC. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010; 58: 398-406.
19. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12: 861-874.
20. Jansson MD and Lund AH. MicroRNA and cancer. Mol Oncol 2012; 6: 590-610.
21. Kasinski AL and Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011; 11: 849-864.
22. Patnaik SK, Kannisto E, Knudsen S and Yendamuri S. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 2010; 70: 36-45.
23. Farhana L, Dawson MI, Murshed F, Das JK, Rishi AK and Fontana JA. Upregulation of miR-150* and miR-630 induces apoptosis in pancreatic cancer cells by targeting IGF-1R. PLoS One 2013; 8: e61015.
24. Huang Y, Guerrero-Preston R and Ratovitski EA. Phospho-ΔNp63α-dependent regulation of autophagic signaling through transcription and micro-RNA modulation. Cell Cycle 2012; 11: 1247.